VEGFA and neoplasm: In a study analyzing 73 tumor samples via immunohistochemistry, the 5-year OS rate of patients with VEGF-C positive and negative oral SCC were found to be significantly different, at 51.7% and 94.2% respectively; VEGF-A, however, was found to be not significantly correlated with survival (24).